Managing Risk and Opportunity for Immediate- and Modified-Release Drug Formulations

Formulators modify the release profiles of drugs for multiple reasons: to target delivery of the API, enhance bioavailability, provide dosage convenience, improve patient adherence, and extend the patentable life cycle of an existing drug.Whether the desired profile is for immediate or modified release, formulators must overcome the development hurdles of poorly soluble APIs. Modified-release drugs may require more excipients and more complex formulations and manufacturing steps, resulting in longer, and more expensive, development processes. Proven formulation methods and careful excipient selection, however, can be employed to develop formulations for modified release drugs that offer value to the patient.
Watch Now

Spotlight

OTHER ON-DEMAND WEBINARS

Designing Pharma organisations for success

pharmatimes

Across all industries, people are changing the ways they engage with products, services, and brands. As a result, life sciences companies find themselves challenged to compete for mindshare in an increasingly noisy market. To stay relevant, pharma marketers must re-evaluate their traditional commercial models and address the changing expectations of their customers—at scale. In this free podcast, Aptus Health in association with PharmaTimes, will explore opportunities pharma marketers have to leverage digital communications to create engaging, high-value experiences for their target markets. We’ll also share examples of how the right technologies and approaches drive meaningful outcomes.
Watch Now

Antioxidants, a safe and viable Inhibition Strategy for Nitrosamine Formation In Drug Products

Nitrosamines are potential mutagens and need to be controlled in human drug products. Recently, nitrosamine contamination of high-profile drugs has prompted numerous recalls, and increased regulatory assessments for marketed products.
Watch Now

Label-Free Techniques for Drug Discovery: Surface Plasmon Resonance (SPR) and MALDI Mass Spectrometry for Primary (HTS) and Secondary Screening

news-medical

The webinar will update on latest developments in MALDI mass spectrometry for high-throughput screening and CPD profiling (rapifleX MALDI PharmaPulse) and introduce Bruker's new surface plasmon resonance (SPR) instrument, the SIERRA SPR-32. Beside technical details explaining the latest developments, synergies between MALDI mass spectrometry and SPR will be discussed.
Watch Now

Fast Tablet Imaging Using FTIR and QCL Microscopy

The composition of pharmaceutical tablets and the distribution of ingredients therein can be determined using chemical imaging by vibrational microscopy.
Watch Now